申联生物控股世之源转型发展“人药”，目标公司尚未盈利

Group 1 - The company Shenyuan Biopharmaceutical (Shanghai) Co., Ltd. plans to acquire a controlling stake in Yangzhou Shizhiyuan Biotechnology Co., Ltd. for 237 million yuan, which will allow it to control 51% of the voting rights [1] - Following the acquisition, the company aims to develop a dual business model focusing on both human pharmaceuticals and animal health, enhancing its innovation drug business [1][3] - The acquisition is expected to lead to an increase in consolidated financial losses and potential risks related to drug development failures and increased financial expenses [1][3] Group 2 - Shizhiyuan is engaged in the research and commercialization of innovative drugs, with three drugs in clinical research stages targeting viral infections and allergic immunity [2] - The financial outlook for Shizhiyuan shows it has not yet achieved profitability, with projected revenues of 164,300 yuan in 2024 and 2.64 million yuan in 2025, alongside net losses of 15.65 million yuan and 12.94 million yuan respectively [3] - The acquisition will integrate Shizhiyuan's core R&D capabilities into the company's human drug sector, aiming to enhance overall innovation capacity and competitiveness [3] Group 3 - The company previously operated in the animal health sector, focusing on the development, production, and sales of veterinary vaccines and drugs, and was the first in the sector to be listed on the STAR Market in 2019 [4] - The animal health industry has faced overcapacity and severe price competition, leading to declining profits for the company, which has seen a continuous drop in net profit since 2021 [5] - The company anticipates a net loss of approximately 20 million yuan in 2025 due to intensified competition and delayed customer payments affecting accounts receivable [5]